<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012999</url>
  </required_header>
  <id_info>
    <org_study_id>32225</org_study_id>
    <nct_id>NCT01012999</nct_id>
  </id_info>
  <brief_title>A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain</brief_title>
  <official_title>Pain Control and Patient Satisfaction: a Dosing Study to Determine a Safe and Effective Dose of Intra-nasal Sufentanil to Treat Emergency Department Patients With Moderate to Severe Pain Due to Extremity Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the appropriate dose and effectiveness of
      intra-nasal administration of a potent narcotic, sufentanil, for the treatment of moderate to
      severe pain due to broken bone(s) in the arm or leg.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty enrolling patients
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief at Thirty Minutes</measure>
    <time_frame>30 min post dose</time_frame>
    <description>Measured pain relief on a visual analog scale (0-10- ten being the worst pain and zero being no pain at all).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Pain</condition>
  <condition>Opiate</condition>
  <arm_group>
    <arm_group_label>Intranasal sufentanil, pain relief</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sufentanil</intervention_name>
    <description>Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period</description>
    <arm_group_label>Intranasal sufentanil, pain relief</arm_group_label>
    <other_name>Sufenta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old or older;

          -  isolated traumatic injury to upper or lower extremity;

          -  alert and oriented to name, date, place; patient has a numeric pain score of 5 or
             higher;

          -  speaks English as their primary language;

          -  female patients are on birth control, menopausal, or are sterile (hysterectomy, tubal
             ligation)

        Exclusion Criteria:

          -  injury isolated to a finger or toe;

          -  previous nasal or sinus surgery; chronic nasal problem;

          -  acute nasal problem (ie epistaxis, upper respiratory infection, sinusitis);

          -  pregnant; prisoner; allergy to sufentanil, fentanyl, or alfentanil; history of
             analgesic abuse or dependency;

          -  presence of other painful injuries; systolic Blood Pressure less than 100 mm Hg;

          -  patient seems or is confused or has a head injury; room air oxygenation less than 95%;

          -  patient has chronic obstructive pulmonary disease, severe asthma, oxygen-dependent
             pulmonary disease;

          -  impaired hepatic or renal function (obtained clinically or by history);

          -  weight more than 230 lbs (100 kg);

          -  alcohol or drug intoxication (per patient admission or clinical assessment of
             physician);

          -  elderly (&gt; 70 years)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Stephen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <results_first_submitted>July 4, 2013</results_first_submitted>
  <results_first_submitted_qc>June 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2017</results_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Robert Stephen, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>acute pain, intranasal, sufentanil,</keyword>
  <keyword>Acute pain control with an intranasal opiate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Over a 2 year period we recruited 16 patients who presented to a single Emergency Department.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intranasal Sufentanil, Pain Relief</title>
          <description>Patients with a suspected acute bony injury to an extremity and in moderate to severe pain.
Intranasal administration, 0.5 mcg/kg, one time dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with a suspected acute bony injury to an extremity and in moderate to severe pain.
Intranasal administration, 0.5-0.9 mcg/kg, maximum dosage of 100 mcg</population>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Sufentanil, Pain Relief</title>
          <description>Patients with a suspected acute bony injury to an extremity and in moderate to severe pain.
Intranasal administration, 0.5 mcg/kg to an extremity and in moderate to severe pain, one time dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Relief at Thirty Minutes</title>
        <description>Measured pain relief on a visual analog scale (0-10- ten being the worst pain and zero being no pain at all).</description>
        <time_frame>30 min post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Sufentanil, Pain Relief</title>
            <description>Patients with a suspected acute bony injury to an extremity and in moderate to severe pain</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief at Thirty Minutes</title>
          <description>Measured pain relief on a visual analog scale (0-10- ten being the worst pain and zero being no pain at all).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Sufentanil, Pain Relief</title>
          <description>Patients with a suspected acute bony injury to an extremity and in moderate to severe pain</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>transient hypoxia</sub_title>
                <description>One patient experienced transient, mild hypoxia that resolved with low flow (2 L NC) oxygen after about 20 minutes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A single episode of transient, mild hypoxia that resolved with 2 L nasal canula oxygen and that completely resolved after 20 minutes and no longer required oxygen</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Stephen, MD</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-587-7653</phone>
      <email>rlstephen@comcast.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

